Ligand Pharma (LGND)
314.78
+8.38 (2.73%)
Upcoming Events
Latest Headlines
Ligand to Report Third Quarter 2026 Financial Results on October 29, 2026
October 15, 2026 7:00 AM - Globe NewsWire
Form 4 LIGAND PHARMACEUTICALS For: Oct 02 Filed by: Reardon Andrew
October 6, 2026 4:36 PM - SEC Filing
Form 4 LIGAND PHARMACEUTICALS For: Sep 22 Filed by: Zimmermann Martine
September 28, 2026 3:31 PM - SEC Filing
Barclays Starts Ligand Pharma (LGND) at Overweight
September 25, 2026 3:16 AM - StreetInsider
Form 4 LIGAND PHARMACEUTICALS For: Sep 22 Filed by: Zimmermann Martine
September 24, 2026 5:22 PM - SEC Filing
Oppenheimer Reiterates Outperform Rating on Ligand Pharma (LGND)
September 24, 2026 9:54 AM - StreetInsider
Form 8-K LIGAND PHARMACEUTICALS For: Sep 24
September 24, 2026 7:15 AM - SEC Filing
Ligand strikes up to $47M financing deal with AvenCell Therapeutics
September 24, 2026 7:01 AM - StreetInsider
Ligand and AvenCell Therapeutics Enter Financing Agreement to Advance Pipeline of Next-Generation CAR-T Therapies for Up to $47 Million
September 24, 2026 7:00 AM - Globe NewsWire
Citi raises Ligand Pharma price target to $397 after royalty deal
September 23, 2026 6:16 AM - StreetInsider
Sydnexis sells EMEA royalty rights to Ligand for $23 million
September 22, 2026 9:05 AM - StreetInsider
Sydnexis Announces Royalty Agreement with Ligand for Ryjunea®
September 22, 2026 9:02 AM - BizWire
Primrose Bio® Raises Significant Growth Capital Investment Led by Signet Healthcare Partners
September 22, 2026 9:01 AM - PR NewsWire
Form 8-K LIGAND PHARMACEUTICALS For: Sep 22
September 22, 2026 7:08 AM - SEC Filing
Ligand pays $23M for royalty stake in pediatric myopia drug Ryjunea
September 22, 2026 7:00 AM - StreetInsider
Ligand Acquires Royalty and Milestone Interest in Santen’s Ryjunea® from Sydnexis for $23 Million
September 22, 2026 7:00 AM - Globe NewsWire
Form 4 LIGAND PHARMACEUTICALS For: Sep 10 Filed by: Zimmermann Martine
September 14, 2026 4:59 PM - SEC Filing
Form 144 LIGAND PHARMACEUTICALS Filed by: Zimmermann Martine
September 10, 2026 4:01 PM - SEC Filing
Ligand to Participate in September Investor Conferences
August 26, 2026 7:00 AM - Globe NewsWire
Form 4 LIGAND PHARMACEUTICALS For: Aug 12 Filed by: Espinoza Octavio
August 14, 2026 5:06 PM - SEC Filing
Form 4 LIGAND PHARMACEUTICALS For: Aug 12 Filed by: Haas Jason
August 14, 2026 5:05 PM - SEC Filing
Leerink Starts Ligand Pharma (LGND) at Outperform
August 14, 2026 9:29 AM - StreetInsider
Ligand Pharma (LGND) Reiterated at Buy by Stifel After Chat With CEO, CFO
August 14, 2026 8:21 AM - StreetInsider
Form SCHEDULE 13G LIGAND PHARMACEUTICALS Filed by: Invesco Ltd.
August 13, 2026 2:59 PM - SEC Filing
Form 144 LIGAND PHARMACEUTICALS Filed by: Espinoza Octavio
August 12, 2026 4:33 PM - SEC Filing
Form 144 LIGAND PHARMACEUTICALS Filed by: Haas Jason
August 12, 2026 4:24 PM - SEC Filing
Form 10-Q LIGAND PHARMACEUTICALS For: Jun 30
August 7, 2026 4:07 PM - SEC Filing
Ligand Pharma (LGND) PT Raised to $345 at RBC Capital
August 7, 2026 7:21 AM - StreetInsider
Ligand Pharma (LGND) Tops Q2 EPS by 42c
August 6, 2026 7:17 AM - StreetInsider
Form 8-K LIGAND PHARMACEUTICALS For: Aug 06
August 6, 2026 7:05 AM - SEC Filing
Ligand Reports Second Quarter 2026 Financial Results
August 6, 2026 7:01 AM - Globe NewsWire
Form 4 LIGAND PHARMACEUTICALS For: Aug 03 Filed by: Reardon Andrew
August 4, 2026 6:43 PM - SEC Filing
Ligand Pharma (LGND) PT Raised to $326 at Oppenheimer
August 3, 2026 5:51 AM - StreetInsider
Ligand to Report Second Quarter 2026 Financial Results on August 6, 2026
July 23, 2026 7:00 AM - Globe NewsWire
Full Article List
